Abiomed Announces Preliminary Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year
(Thomson Reuters ONE) -
Largest Quarterly Sequential Revenue Increase in Company History
DANVERS, Mass. and SAN FRANCISCO, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Abiomed,
Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support
technologies today reported preliminary, unaudited, third quarter fiscal 2017
revenue of approximately $114.7 million, an increase of 34% compared to revenue
of $85.8 million for the same period of fiscal 2016.
* Preliminary unaudited U.S. revenue from Impella® products grew 34% to
approximately $100.3 million from $75.0 million in the prior fiscal year.
* For the third quarter of fiscal 2017, U.S. patient usage grew 32% in
comparison with same period of fiscal 2016. Protected PCI patient usage grew
34% and emergent patient usage grew 36%, year-over-year.
The preliminary unaudited revenue results described in this press release are
estimates only and are subject to revision until the Company reports its full
financial results for the third quarter of fiscal 2017 on January 26, 2017.
These preliminary results are being provided in advance of the Company's
presentation at the 35th Annual J.P. Morgan Healthcare Conference at the Westin
St. Francis Hotel in San Francisco. Michael R. Minogue, Chairman, President and
Chief Executive Officer, Abiomed, will present at 9:30 a.m. PT/12:30 p.m. ET on
Wednesday, January 11, 2017.
A live webcast of the Company's presentation at the conference will be available
via http://jpmorgan.metameetings.com/confbook/healthcare17/directlink?p=22722 as
well as on the investor section of the Company's website at www.abiomed.com. A
replay of the webcast will be available for 90 days after the presentation.
FISCAL YEAR 2017 OUTLOOK
The Company is maintaining its fiscal year 2017 revenue guidance of $435 million
to $445 million, an increase in revenue of 32% to 35% from the prior year. The
Company is also maintaining its fiscal year guidance for GAAP operating margin
to be in the range of 18% to 20%.
EARNINGS CONFERENCE CALL DETAILS
The Company will release full quarterly results for the third quarter of fiscal
2017 and update the fiscal 2017 guidance via conference call on Thursday,
January 26, 2017.
The conference call releasing full quarterly results will be hosted by Michael
R. Minogue, Chairman, President and Chief Executive Officer and Michael
Tomsicek, Vice President and Chief Financial Officer.
To listen to the call live, please tune into the webcast
via http://investor.abiomed.com or dial (855) 212-2361; the international number
is (678) 809-1538. A replay of this conference call will be available beginning
at 11 a.m. EST January 26, 2017 through 11 a.m. EST on January 29, 2017. The
replay phone number is (855) 859-2056; the international number is (404)
537-3406. The replay access code is 44227123.
The ABIOMED logo, ABIOMED, Impella CP, Impella RP and Symphony are registered
trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries. Impella
2.5, Impella 5.0, Impella LD, Impella BTR, Impella cVAD, Impella ECP and
Recovering hearts. Saving lives. are trademarks of Abiomed, Inc.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical
devices that provide circulatory support. Our products are designed to enable
the heart to rest by improving blood flow and/or performing the pumping of the
heart. For additional information, please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding
development of Abiomed's existing and new products, the Company's progress
toward commercial growth, and future opportunities and expected regulatory
approvals. The Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number of factors,
including uncertainties associated with development, testing and related
regulatory approvals, including the potential for future losses, complex
manufacturing, high quality requirements, dependence on limited sources of
supply, competition, technological change, government regulation, litigation
matters, future capital needs and uncertainty of additional financing, and other
risks and challenges detailed in the Company's filings with the Securities and
Exchange Commission, including the most recently filed Annual Report on Form 10-
K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue
reliance on any forward-looking statements, which speak only as of the date of
this release. The Company undertakes no obligation to publicly release the
results of any revisions to these forward looking statements that may be made to
reflect events or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
For further information please contact:
Ingrid Goldberg,
Director, Investor Relations
978-646-1590
ir(at)abiomed.com
Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith(at)abiomed.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 09.01.2017 - 22:01 Uhr
Sprache: Deutsch
News-ID 516578
Anzahl Zeichen: 6021
contact information:
Town:
Danvers
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 258 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Abiomed Announces Preliminary Q3 FY 2017 Revenue of $114.7 Million, Up 34% Over Prior Year"
steht unter der journalistisch-redaktionellen Verantwortung von
Abiomed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
